Alcresta Therapeutics, Inc. — Form D/A
Alcresta Therapeutics, Inc. of WARREN, NJ, a company, filed a Form D amendment with the SEC on 2016-10-31. The offering totals $50.9M, of which $50.9M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2016-10-31
- Form: D/A
- Accession: 0001140361-16-084182
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $50.9M
- Amount sold: $50.9M
- Investors: 13
- Date of first sale: 2016-03-22
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-264996
Issuer
- Name: Alcresta Therapeutics, Inc.
- CIK: 0001673510
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2011
- Address: 15 INDEPENDENCE BOULEVARD, WARREN, NJ, 07059
- Phone: 617 431 3600
Officers, directors & promoters (20)
| Name | Role | Location |
|---|
| Stephen Krauss | Director | Newton, MA |
| Jeremy Lack | Director | Newton, MA |
| Robert Gallotto | Executive Officer | Newton, MA |
| Tasos Konidaris | Executive Officer | Newton, MA |
| Garheng Kong | Director | Seattle, WA |
| James Topper | Director | La Jolla, CA |
| Daniel Tasse | Director | Chatillon, I0 |
| Daniel Tasse | Executive Officer | Chatillon, I0 |
| Stephen Kraus | Director | Berwyn, PA |
| Todd Creech | Director | Jacksonville, FL |
| Anastasios Konidaris | Director | Warren, NJ |
| Anastasios Konidaris | Executive Officer | Warren, NJ |
| William Scheinler | Executive Officer | Warren, NJ |
| Alexey Margolin | Director | Warren, NJ |
| Steve Dubin | Director | Warren, NJ |
| Daniel Orlando | Director | Warren, NJ |
| Daniel Orlando | Executive Officer | Warren, NJ |
| Eric First | Executive Officer | Warren, NJ |
| Martin Paz | Executive Officer | Warren, NJ |
| James Gamgort | Executive Officer | Warren, NJ |
Other filings by this issuer (4)
More